<?xml version="1.0" encoding="UTF-8"?>
<mods xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.1" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
  <titleInfo>
    <title>Modern biopharmaceuticals : recent success stories</title>
  </titleInfo>
  <name type="personal">
    <namePart>Knäblein, Jörg.</namePart>
  </name>
  <typeOfResource>text</typeOfResource>
  <genre authority="">Electronic books.</genre>
  <originInfo>
    <place>
      <placeTerm type="code" authority="marccountry">gw</placeTerm>
    </place>
    <place>
      <placeTerm type="text">Weinheim</placeTerm>
    </place>
    <publisher>Wiley-VCH Verlag GmbH</publisher>
    <dateIssued>2013</dateIssued>
    <issuance>monographic</issuance>
  </originInfo>
  <language>
    <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
  </language>
  <physicalDescription>
    <form authority="gmd">electronic resource</form>
    <reformattingQuality>access</reformattingQuality>
    <extent>1 online resource (450 pages)</extent>
  </physicalDescription>
  <tableOfContents>Related Titles; Title Page; Copyright; Dedication; Foreword by Andreas Busch; Foreword by Günter Stock; Preface; Quotes; List of Contributors; Part I: Modern Biopharmaceuticals: Research is the Best Medicine -- Sanitas Summum Bonus; Chapter 1: Twenty Thousand Years of Biotech -- From "Traditional" to "Modern Biotechnology"; 1.1 Biotechnology -- The Science Creating Life; 1.2 The Inauguration of Biotechnology; 1.3 From "Traditional" to "Modern Biotechnology"; 1.4 A Small Molecule from Bacteria -- A Huge Importance for Mankind; 1.5 Biopharmaceuticals -- The Mainstay of Modern Biotechnology</tableOfContents>
  <tableOfContents>1.6 Transformation of the Pharma Industry Through Biotechnology1.7 Biopharmaceutical Production -- Uncorking Bottlenecks or Wasting Surplus Capacity?; 1.8 Conclusion and Outlook; References; Part II: Modern Biopharmaceutical Development Using Stem Cells, Tissues, and Whole Animals; Chapter 2: Induced Pluripotency as Substitute of Somatic Cell Nuclear Transfer? -- The Impact of Induced Pluripotent Stem Cells on Drug Discovery and Regenerative Biopharmaceuticals; 2.1 Introduction; 2.2 Derivation and Growth of hESC; 2.3 Signaling Pathways and Transcription Factors</tableOfContents>
  <tableOfContents>2.4 Differentiation and Applications of hESC2.5 Patient-Specific Nuclear Transfer Stem Cells; 2.6 Patient-Specific Pluripotent Cells Through Direct Reprogramming of Adult Somatic Cells; 2.7 Concluding Remarks and Outlook; Acknowledgment; References; Chapter 3: Pluripotent Stem Cell-Derived Cardiomyocytes for Industrial and Clinical Applications; 3.1 Introduction; 3.2 Pluripotent Stem Cells; 3.3 High-Yield Differentiation of Pluripotent Stem Cells into Cardiomyocytes; 3.4 Purification of Pluripotent Stem Cell-Derived Cardiomyocytes; 3.5 Cardiomyocytes at an Industrial Scale</tableOfContents>
  <tableOfContents>3.6 Utilization of Tissue Engineering Technologies to Advance Cellular Maturity3.7 Concluding Remarks; References; Chapter 4: Industrialization of Functional Mouse Genomics Technologies for Biopharmaceutical Drug Discovery and Development; 4.1 Introduction; 4.2 The Mouse Genetics Story; 4.3 Establishing Inducible Gene Targeting Tools; 4.4 RNAi -- Talking About a Revolution?; 4.5 Further Shortening the Generation Timeline for RNAi Mouse Models; 4.6 Adapting the Mouse Genetics Toolbox for New Applications; References; Part III: Innovative Development Tools for Modern Biopharmaceuticals</tableOfContents>
  <tableOfContents>Chapter 5: Standardized Solutions for Quantitative and Real-Time RT-PCR to Accelerate Biopharmaceutical Development5.1 Introduction; 5.2 Potential of Real-Time RT-PCR in Biopharmaceutical Development; 5.3 Accurate Gene Expression Analysis Depends on Standardized Preanalytical Steps; 5.4 Accuracy of Real-Time RT-PCR Depends on Efficient cDNA Synthesis; 5.5 Integration of Preanalytical Steps Streamlines Gene Expression Analysis; 5.6 Overview of Methods for Real-Time RT-PCR; 5.7 Developments in Real-Time PCR Instrumentation; 5.8 The Need for Better Standardization of Quantification Methods</tableOfContents>
  <targetAudience authority="marctarget">specialized</targetAudience>
  <note type="statement of responsibility">edited by Jorg Knablein.</note>
  <subject authority="lcsh">
    <topic>Biopharmaceutics</topic>
  </subject>
  <subject authority="fast">
    <topic>Biopharmaceutics</topic>
  </subject>
  <classification authority="lcc">RM301.4</classification>
  <classification authority="ddc" edition="22">615.1/9</classification>
  <classification authority="nlm">QV 38</classification>
  <relatedItem type="otherFormat" displayLabel="Print version:"/>
  <identifier type="isbn">9783527669417</identifier>
  <identifier type="isbn">3527669418</identifier>
  <identifier type="isbn">9781299448902</identifier>
  <identifier type="isbn">1299448909</identifier>
  <identifier type="isbn" invalid="yes"/>
  <identifier type="isbn" invalid="yes"/>
  <identifier type="stock number">476140 MIL</identifier>
  <identifier type="uri">http://onlinelibrary.wiley.com/book/10.1002/9783527669417</identifier>
  <location>
    <url>http://onlinelibrary.wiley.com/book/10.1002/9783527669417</url>
  </location>
  <recordInfo>
    <recordContentSource authority="marcorg">CDX</recordContentSource>
    <recordCreationDate encoding="marc">110329</recordCreationDate>
    <recordChangeDate encoding="iso8601">20171106115917.0</recordChangeDate>
    <recordIdentifier source="OCoLC">ocn842412695</recordIdentifier>
    <languageOfCataloging>
      <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
    </languageOfCataloging>
  </recordInfo>
</mods>
